Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

October 11, 2005; 65 (7) Brief Communications

Evidence for progressive gray matter loss in patients with relapsing-remitting MS

P. Valsasina, B. Benedetti, M. Rovaris, M. P. Sormani, G. Comi, M. Filippi
First published October 10, 2005, DOI: https://doi.org/10.1212/01.wnl.0000178982.53965.70
P. Valsasina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Benedetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Rovaris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. P. Sormani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Comi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Filippi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Evidence for progressive gray matter loss in patients with relapsing-remitting MS
P. Valsasina, B. Benedetti, M. Rovaris, M. P. Sormani, G. Comi, M. Filippi
Neurology Oct 2005, 65 (7) 1126-1128; DOI: 10.1212/01.wnl.0000178982.53965.70

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
392

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Little is known about the temporal evolution of gray matter damage occurring early in the course of multiple sclerosis (MS). The authors investigated the evolution of gray matter volume loss in 117 patients with relapsing–remitting MS, scanned monthly for a 9-month period. Time-trend analysis revealed a decrease of gray matter volumes over the study period (p < 0.001). This study shows that gray matter damage in relapsing–remitting MS evolves markedly over a short period of observation.

Assessing brain volume changes on serial MRI scans is an established, reliable way to estimate the amount of progressive tissue loss known to occur in patients with multiple sclerosis (MS) as a result of neurodegeneration.1 Brain atrophy is a consistent feature of all MS phenotypes,2 and progressive brain tissue loss can be observed at the earliest clinical stage of the disease.3 Additional MRI work has shown that tissue loss and intrinsic damage2,4 of cerebral gray matter (GM) might also contribute to the development of overall brain atrophy.1

To our knowledge, only one preliminary study has explored the temporal evolution of GM loss in 13 patients with early relapsing–remitting MS (RRMS) followed up with MRI every 6 months for 18 months.5 In this study, we investigated the temporal profile of GM volume changes and how such changes relate to other MRI markers of MS evolution in a large sample of patients with more advanced RRMS who underwent monthly MRI scans over a period of 9 months as the placebo arm of a treatment trial.6

Methods.

The current analysis is based on MRI data from the patients enrolled in the placebo arm of the European/Canadian glatiramer acetate trial.6 All patients had RRMS and underwent physical and neurologic examination and brain MRI at screening, at baseline, and every month for 9 months. Conventional spin-echo sequences were used to obtain proton density (PD) and T2-weighted images. Two series of T1-weighted images were obtained before and after the injection of 0.1 mmol/kg of gadolinium (Gd). For each visit, T2-hyperintense, T1-hypointense, and Gd-enhancing lesion volumes (LVs) were calculated using a semiautomated technique. Additional information about trial design and MRI acquisition/postprocessing is reported elsewhere.6 On the precontrast T1-weighted images, normalized GM volumes were measured using SIENAx, the cross-sectional version of the SIENA (Structural Imaging Evaluation of Normalized Atrophy) software.7 SIENAx uses a brain extraction tool to perform segmentation of brain from nonbrain tissue in the head and to estimate the skull surface. Then, the extracted brain image is segmented into white matter (WM), GM, and CSF, yielding an estimate of the absolute volumes of brain tissue compartments. The original MRI image is registered to a canonical image in a standardized space (derived from the MNI152 standard space) to provide a spatial normalization scaling factor for each patient. The estimated absolute volumes for each subject are then multiplied by the normalization factor to yield a normalized parenchymal volume of these tissue compartments. To test the reproducibility of this technique, we repeated the measurements of normalized GM, WM, and normalized brain volumes on the whole set of scans belonging to 10 randomly selected patients. For each metric, the measurement variability was assessed by using the coefficient of variation (CoV), defined as the SD of a given variable divided by its mean value.

We investigated the time trend of GM volumes using a mixed random effect model, which accounted for the autocorrelation of repeated measures within each patient. This model was corrected with an adjustment for baseline GM volumes. The correlations between GM volume changes over the study period and other MRI parameters were assessed using the Spearman rank correlation coefficient.

Results.

Data for GM volume measurements were usable from 117 of 120 patients (97.5%). Three of the 120 patients originally assigned to the placebo arm did not contribute to the current analysis because of suboptimal image quality of 5 or more of the available 10 scans/patient, which prevented a reliable application of SIENAx to define an accurate temporal profile of GM volume changes. Clinical and MRI findings at baseline and follow-up are reported in the table. The mean values of the intraobserver CoVs were 0.01% (range = 0.007 to 0.03%) for normalized GM volume, 0.02% (range = 0.002 to 0.07%) for normalized WM volume, and 0.004% (range = 0.001-0.006%) for normalized brain volume measurements. The time–trend analysis revealed a progressive GM volume decrease over the study period (p < 0.001), with an estimated mean percentage change per month of −0.30%, whereas WM volume did not change significantly over the study period (figure). These results did not change when correcting for the corresponding LVs (data not shown). GM volume at baseline was correlated with the corresponding T2-hyperintense (r = −0.40, p < 0.001) and T1-hypointense (r = −0.22, p = 0.015) LVs. No significant correlation was found between the change of GM volume and those of other MRI parameters over the study period.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table Clinical and MRI characteristics of the study subjects

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Average normalized gray matter (A), white matter (B), and total brain volumes (C) and 95% CIs (bars) as detected by monthly scans over a 9-month follow up in 117 untreated patients with relapsing–remitting multiple sclerosis.

Discussion.

Our results are consistent with those of a previous longitudinal study5 of 13 patients with RRMS followed up for 18 months, with MRI obtained every 6 months. Although the duration of our follow-up was shorter than that of the previous report,5 we believe that the current study adds to the existing literature, because it was conducted on a much larger sample of patients, who also had a longer disease duration (mean of 8.3 vs 1.9 years). Another strength of the current study is the frequent sampling of MRI data, which allowed an accurate estimate of the temporal profile of GM damage. The results of these two studies taken together suggest that progressive GM loss is a consistent feature of MS in its relapsing–remitting phase. GM tissue loss might be preceded or accompanied by progressive intrinsic GM damage, as shown by a recent longitudinal study of RRMS followed for 18 months, with diffusion tensor MRI obtained every 3 months.5 In accord with previous evidence highlighting the clinical relevance of GM damage in MS,8 these results may also have important implications for the planning of trials of neuroprotective therapies in RRMS, where GM volume changes might serve as a meaningful measure of outcome.

White matter volume stability in RRMS might be the result of an earlier onset of WM atrophy, as shown by a study in patients with clinically isolated syndromes suggestive of demyelination,9 where WM but not GM atrophy was found. Another, but not mutually exclusive, explanation for WM volume stability might be that WM atrophy does also occur in RRMS patients but is masked by edema and cellular infiltration associated with inflammation, which is known to occur at a much lesser extent in GM.10

Two possible mechanisms (not mutually exclusive) can explain the presence of evolving GM pathology in MS: the progressive accumulation of GM lesions and neuronal damage due to retrograde degeneration of axons passing through WM lesions. The latter explanation is supported by our finding of a correlation between GM volume and MRI-visible lesion burdens at baseline, which is in keeping with the results of other studies.2,5 Nevertheless, the lack of significant correlation between GM atrophy development and increased WM lesion loads also suggests that GM pathology cannot only be a consequence of WM damage, and that MS-related damage to the two brain tissue compartments may follow distinct patholobiogical pathways. Despite a previous post mortem study that found abundant axonal transection in active lesions from patients with MS,10 we did not find any significant correlation between evolving GM atrophy and enhancing LV changes. This might be explained by the relative paucity of enhancing lesions, which typically represent a small part of the overall brain tissue, or by the relatively short duration of the follow-up, which prevented us from investigating a possible long-term effect of inflammation on GM tissue loss.

Acknowledgment

The authors thank Teva for allowing us to conduct this natural history analysis using data from placebo patients enrolled in the European/Canadian MRI-monitored trial of glatiramer acetate.

Footnotes

  • Disclosure: M. Filippi, MD, G. Comi, MD, M. Rovaris, MD, and M.P. Sormani, PhD, received honoraria—M. Filippi and G. Comi's honoraria exceeded $10,000—from TEVA for their participation in the MRI-monitored European/Canadian glatiramer acetate trial. This study is based on the placebo data of the above-mentioned trial but was conducted independently and without any sponsorship.

    Received April 1, 2005. Accepted in final form June 16, 2005.

References

  1. 1.↵
    Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–1695.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Quarantelli M, Ciarmiello A, Brescia Morra V, et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18:360–366.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489–1496.
    OpenUrlCrossRefPubMed
  4. 4.
    Oreja-Guevara C, Rovaris M, Iannucci G, et al. Progressive grey matter damage in patients with relapsing-remitting MS: a longitudinal diffusion tensor MRI study. Arch Neurol 2005;62:578–584.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Chard DT, Griffin CM, Rashid W, et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004;10:387–391.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290–297.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–489.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Chen JT, Narayanan S, Collins DL, et al. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004;23:1168–1175.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Traboulsee A, Dehmeshki J, Brex PA, et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002;59:126–128.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407–1419.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis
  • MRI
  • Volumetric MRI

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise